Q3 Product Revenue Up 10% to $57.7M, Net Loss Narrows to $0.6M
CERS sits 93% above its 52-week low of $1.38.
Summary
Cerus posted Q3 2026 product revenue of $57.7 million, up 10% year over year, with total revenue of $64.0 million versus $60.2 million. The net loss attributable to Cerus narrowed to $0.6 million from $0.02 million a year ago, and adjusted EBITDA came in at positive $5.7 million versus $5.0 million. Growth came from U.S. IFC sales of $5.6 million (up from $3.9 million), the U.S. platelet franchise, and INT200 illuminator sales in EMEA, while product gross margin slipped to 52.4% from 53.4% on a weaker dollar and inflation. Management reiterated full-year 2026 product revenue guidance of $229 million to $231 million, implying 11% to 12% growth, and ended the quarter with $57.1 million in cash and short-term investments after generating $3.0 million from operations. The release also folds in today's positive Phase 3 RedeS topline results for INTERCEPT red blood cells, which management will discuss on the 4:30 P.M. ET call.
At the time of this announcement, CERS was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $475.6M. The 52-week trading range was $1.38 to $3.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.